Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea
· Delayed Price · Currency is KRW 96,000
+3,200 (3.45%)
Apr 29, 2026, 3:30 PM KST
Mezzion Pharma Revenue
In the year 2025, Mezzion Pharma had annual revenue of 7.91B KRW, down -8.15%. Mezzion Pharma had revenue of 2.08B in the quarter ending December 31, 2025, with 8.32% growth.
Revenue
7.91B
Revenue Growth
-8.15%
P/S Ratio
356.58
Revenue / Employee
439.42M
Employees
18
Market Cap
2,820.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.91B | -702.12M | -8.15% |
| Dec 31, 2024 | 8.61B | -23.11B | -72.85% |
| Dec 31, 2023 | 31.72B | 994.76M | 3.24% |
| Dec 31, 2022 | 30.73B | 4.07B | 15.28% |
| Dec 31, 2021 | 26.65B | -1.98B | -6.92% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,814.00B |
| Celltrion | 4,162.50B |
| ALTEOGEN | 215.86B |
| Samsung Epis Holdings | 1,510.14B |
| ST Pharm | 331.68B |
| PharmaResearch | 536.29B |
| SK bioscience | 651.37B |
| Hugel | 425.11B |